A5035769119- Amyloidosis: Diagnosis, Treatment, Outcomes
- Heart Failure Treatment and Management
- Parathyroid Disorders and Treatments
- Cardiovascular Function and Risk Factors
- Peptidase Inhibition and Analysis
- Cardiac pacing and defibrillation studies
- Cardiomyopathy and Myosin Studies
- Cardiac electrophysiology and arrhythmias
- Medical Imaging and Pathology Studies
- Cardiac Imaging and Diagnostics
- Eosinophilic Disorders and Syndromes
- Cardiac Structural Anomalies and Repair
- Atrial Fibrillation Management and Outcomes
- Hormonal Regulation and Hypertension
- Acute Myocardial Infarction Research
- Neuroendocrine Tumor Research Advances
- Cardiac Fibrosis and Remodeling
- Sarcoidosis and Beryllium Toxicity Research
- IL-33, ST2, and ILC Pathways
- Cardiovascular Effects of Exercise
- Cardiac Arrhythmias and Treatments
- Genetic Neurodegenerative Diseases
- Protein Kinase Regulation and GTPase Signaling
- Diabetes Treatment and Management
- Obstructive Sleep Apnea Research
Scuola Superiore Sant'Anna
2016-2025
Fondazione Toscana Gabriele Monasterio
2016-2025
Ospedale Cisanello
2025
Ospedale generale di zona San Camillo Treviso
2025
Ospedale per gli Infermi
2025
University College London
2024
University of Florence
2013-2023
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2023
Azienda Ospedaliero-Universitaria di Modena
2023
University of Pisa
2018-2023
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. goal of this study was the prognostic importance an increase in N-terminal pro–B-type natriuretic peptide (NT-proBNP) outpatient diuretic intensification (ODI) as markers progression large cohort patients with ATTR-CA. We evaluated landmark survival analysis based on worsening NT-proBNP requirement for...
Galectin-3 (Gal-3) is involved in inflammation, fibrogenesis, and cardiac remodeling. Previous evidence shows that Gal-3 interacts with aldosterone promoting macrophage infiltration vascular fibrosis genetic pharmacological inhibition prevents remodeling a pressure-overload animal model of heart failure. We aimed to explore the contribution mechanisms leading failure murine model. Male mice cardiac-specific hyperaldosteronism underwent isoproterenol subcutaneous injections, be then...
Background A thorough analysis of noncardiac determinants mortality in heart failure ( HF ) is missing. Furthermore, evidence conflicts on the outcome patients with and no or mild systolic dysfunction. We aimed to investigate prevalence cardiac causes death a cohort chronic patients, covering whole spectrum function. Methods Results enrolled 2791 stable classified into reduced ejection fraction r EF ; left ventricular [EF] <40%), HR midrange mr 41–49%), preserved p ≥50%), followed up for...
Background The relative contribution of amyloid and fibrosis to extracellular volume expansion in cardiac amyloidosis (CA) has never been defined. Methods Results We included all patients diagnosed with light-chain (AL) or transthyretin at a tertiary referral center between 2014 2020 undergoing left ventricular endomyocardial biopsy. Patients (n=37) were more often men (92%), median age 72 years (interquartile range, 68-81). Lambda-positive AL was found 14 19 cases (38%) kappa-positive 5...
Background Intracardiac thrombosis is reported to occur frequently in cardiac amyloidosis (CA). However, data regarding arterial thrombo-embolic events (AEs) CA are limited. We aimed at assessing prevalence, clinical characteristics and predictors of AEs a large multicentric cohort.Methods results Four-hundred-six consecutive patients (134 AL, 73 ATTRm 199 ATTRwt) from 5 Italian referral centres were retrospectively evaluated followed-up for median time 19 months. Thirty-one (7.6%) suffered...
Cardiac amyloidosis (CA) affects the four heart chambers, which can all be evaluated through speckle-tracking echocardiography (STE).We 423 consecutive patients screened for CA over 5 years at two referral centres. was diagnosed in 261 (62%) with either amyloid transthyretin (ATTR; n = 144, 34%) or light-chain (AL; 117, 28%) CA. Strain parameters of chambers were altered patients, particularly those ATTR-CA. Nonetheless, only peak left atrial longitudinal strain (LA-PALS) displayed an...